Clinical trial
An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)
NCT05641688 is registered in ClinicalTrials.gov with Lantheus Biosciences Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Non-randomized, Multi-center Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of PET Imaging With [18F]PI-2620 for the Detection of Tau Deposition When Compared to Post-mortem Histopathology (ADvance)
- Lead sponsor
- Lantheus Biosciences Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2022
- Completion date
- June 30, 2027
- Enrollment
- 200 (estimated)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.